Drugs / BNC210
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT05193409 | Feb → Oct 2022 | social phobia | Bionomics Limited | Completed | Missed primary |
| Phase 2 | NCT04951076 | Jul 2021 → Jul 2023 | post-traumatic stress disorder | Bionomics Limited | Completed | No outcome recorded |
| Phase 2 | NCT03548194 | May 2018 → Apr 2019 | — | Bionomics Limited | Completed | No outcome recorded |
| Phase 2 | NCT02933606 | Jun 2016 → Jul 2018 | post-traumatic stress disorder | Bionomics Limited | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT06510504 | Aug 2024 → Sep 2025 | social phobia | Bionomics Limited | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNC210 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05193409 ↗ |
| Known as | Iw-2143 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650452 ↗ |
| Action | Inhibit | “BNC210 is a novel α7 nicotinic acetylcholine receptor-negative allosteric modulator developed to treat PTSD.” PMID 39647171 ↗ Dec 20241“Neuronal acetylcholine receptor protein alpha-7 subunit negative allosteric modulator” CHEMBL4650452 ↗ |
| Route | Oral | “Suspension administered orally for 12 weeks.” NCT02933606 ↗ |
| Target | CHRNA7 | “Neuronal acetylcholine receptor protein alpha-7 subunit negative allosteric modulator” CHEMBL4650452 ↗ |